camrelizumab   Click here for help

GtoPdb Ligand ID: 9758

Synonyms: INCSHR1210 | SHR-1210
Approved drug Immunopharmacology Ligand
camrelizumab is an approved drug (China (2019))
Compound class: Antibody
Comment: Camrelizumab is a fully human anti-programmed cell death 1 (PD-1) monoclonal antibody being developed as an immuno-oncology therapeutic.

SARS-CoV-2 and COVID-19: Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 will be evaluated in clinical trial NCT04268537.
No information available.
Summary of Clinical Use Click here for help
More than 20 clinical trials assessing camrelizumab's anti-tumour activity are registered with ClinicalTrials.gov. The most advanced trials are two Phase 3 clinical trials evaluating camrelizumab's efficacy against lung cancer (NCT03134872) and esophageal carcinoma (NCT03099382). The first global approval of camrelizumab was granted by China in 2019, under which camrelizumab is indicated as a treatment for relapsed/refractory classical Hodgkin lymphoma [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03099382 Study of SHR-1210 Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal Cancer Phase 3 Interventional Jiangsu HengRui Medicine Co., Ltd.
NCT03134872 A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC Phase 3 Interventional Jiangsu HengRui Medicine Co., Ltd.
NCT04268537 Immunoregulatory Therapy for 2019-nCoV Phase 2 Interventional Southeast University, China PD-1 blockade is anticipated to reduce the development of sepsis secondary to severe pneumonia and excessive inflammatory response syndrome in COVID-19 patients, by reversing sepsis-associated T cell depletion.